Cleared Traditional

K013180 - RAPIDONE-ECSTASY TEST

K013180 is an FDA 510(k) clearance for RAPIDONE-ECSTASY TEST, manufactured by American Bio Medica Corp.. The device is a Class 2 Toxicology device with product code DJC cleared through the Traditional 510(k) pathway after a 63-day FDA review.

K013180 · American Bio Medica Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2001
Decision
63d
Days
Class 2
Risk

K013180 is an FDA 510(k) clearance for the RAPIDONE-ECSTASY TEST. Classified as Thin Layer Chromatography, Methamphetamine (product code DJC), Class II - Special Controls.

Submitted by American Bio Medica Corp. (Columbia, US). The FDA issued a Cleared decision on November 26, 2001 after a review of 63 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3610 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all American Bio Medica Corp. devices

FDA 510(k) Submission Details - K013180

510(k) Number K013180 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 24, 2001
Decision Date November 26, 2001
Days to Decision 63 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
24d faster than avg
Panel avg: 87d · This submission: 63d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DJC Device Classification - Class 2, Special Controls

Product Code DJC Thin Layer Chromatography, Methamphetamine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3610
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJC Thin Layer Chromatography, Methamphetamine

All 17
Devices cleared under the same product code (DJC) and FDA review panel - the closest regulatory comparables to K013180.
WONDFO OXAZEPAM URINE TEST (BZO 200) AND WONDFO METHAMPHETAMINE URINE TEST (MET 300)
K132630 · Guangzhou Wondfo Biotech Co., Ltd. · Sep 2013
INSTANT-VIEW MDMA (ECSTASY, XTC) URINE TEST
K022501 · Alfa Scientific Designs, Inc. · Nov 2002
VERDICT-II
K022141 · Medtox Diagnostics, Inc. · Jul 2002
VERDICT -II METHAMPHETAMINE
K010226 · Medtox Diagnostics, Inc. · Jun 2001
INSTANT-VIEW METHAMPHETAMINE URINE DIP STRIP TEST
K994406 · Alfa Scientific Designs, Inc. · Aug 2000
INSTANT-VIEW METHAMPHETAMINE URINE CASSETTE TEST
K994400 · Alfa Scientific Designs, Inc. · Aug 2000